Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock

As infection control improves and circulation stabilizes, treatment de-escalation of septic shock begins, accompanied by fluid redistribution from interstitial spaces to the vasculature, increasing cardiac volume load. Synthetic recombinant human BNP (rh-BNP) plays a role in inducing vasodilation, particularly in the venous system, alleviating cardiac congestion, and enhancing natriuresis and diuresis. Thus the investigators designed a single-center, prospective physiological study to evaluate the efficacy of standard rh-BNP infusion in reducing venous return and enhancing fluid removal, with a secondary objective of assessing the maintenance of perfusion pressure and tissue perfusion.

NCT Number	NCT06745206
Lead Sponsor	Sichuan Provincial People's Hospital Collaborators: Tibet Kangzhe Pharmaceutical Development Co., Ltd
Conditions	Sepsis-induced Cardiomyopathy, the Recovery Phase of Septic Shock
Enrollment	30 participants
Start Date	2025-12
Primary Completion	2026-06 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2025-07-29